The SaaS Weekly is a weekly newsletter covering major SaaS news from Canada and around the globe.
Subscribe to S|W using the form at the bottom of this page to ensure you don’t miss out on the most important SaaS news every week!
Breather recruits CTO to expand product suite, hire in Montreal(BETAKIT)
Breather has announced that Philippe Bouffaut, former head of engineering in Canada for Cision, will take the role of Breather’s CTO.
Ping Identity files for $100M IPO on Nasdaq to trade as ‘PING’(TECHCRUNCH)
While the initial S-1 filing doesn’t have an indication of price range, Ping is said to be looking at a valuation of between $2 billion and $3 billion in this listing.
Spa-salon SaaS startup Zenoti raises $20 Mn from Steadview(INC42)
Zenoti says it would use the funding to enter new categories such as pet and car spas.
Paris-based DataHawk raises €1.2 million for its SaaS platform to help e-merchants grow on Amazon(EUSTARTUPS)
Founded in 2019, Paris-based DataHawk has created a data analysis platform to help e-merchants grow on Amazon.
NexTech AR closes $1,161,780 to expand AR entertainment studio(BETAKIT)
NexTech AR, which develops an augmented reality (AR) advertising platform, has closed $1,161,780 in a private placement.
VMware acquires Carbon Black for $2.1B and Pivotal for $2.7 billion(TECHCRUNCH)
The two moves follow the company’s acquisition of Bitnami earlier this year, completing this triquetra of acquisitions that all aim to bring VMware’s technology into a future where VMs are only part of the equation.
How SaaS is changing the way we work(ENTREPRENEUR)
As SaaS continues to help businesses and individuals work more efficiently, the world has taken notice.
Munich-based augmented reality startup eyecandylab raises €1.35 million seed round(EUSTARTUPS)
Eyecandylab provides a computer-vision software solution using videos as a trigger for AR content on consumer mobiles and AR glasses.
Remediant lands $15M Series A to disrupt privileged access security(TECHCRUNCH)
Remediant’s co-founders, Paul Lanzi and Tim Keeler, worked in biotech for years and saw a problem first-hand with the way companies secured privileged access.
